GHITM

Across TCGA pan-cancer cohorts, GHITM mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GHITM data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GHITM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GHITM expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where GHITM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.722	0.917	.004	27	view →
CCRCC	DFS	Median	All	0.716	0.893	.016	14	view →
PDAC	DFS	Quartile	All	0.275	0.660	.008	9	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
UCEC	DFS	Tertile	All	0.873	1.000	.047	2	view →
GBM	OS	Median	All	0.872	0.695	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GHITM–LUAD (OS)

Open the LUAD breakdown →